ONT-380: Additional Phase Ib data

Additional data from 32 evaluable patients with HER2-positive metastatic breast cancer who were heavily pretreated with Herceptin trastuzumab and a taxane

Read the full 212 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE